azn201306126k2.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2013
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
12 June 2013
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 11 June 2013, Briggs Morrison, EVP, Global Medicines Development & Chief Medical Officer, a person discharging managerial responsibilities, was granted awards under the terms of the AstraZeneca Investment Plan (AZIP) and the AstraZeneca Performance Share Plan (AZPSP) over the Company's American Depositary Shares (ADSs) as detailed below. One ADS equals one ordinary share. A summary of these plans can be found in the AstraZeneca Annual Report and Form 20-F Information 2012 which is available on the Company's website www.astrazeneca.com.
|
Name
|
Shares awarded under AZIP
|
Shares awarded under AZPSP
|
Award price per share
|
|
Briggs Morrison
|
6,472
|
38,833
|
$51.45
|
The AZIP award is subject to a four-year performance period (1 January 2013 to 31 December 2016) and a subsequent four-year holding period (1 January 2017 to 31 December 2020).
The AZPSP award is subject to a three-year performance period (1 January 2013 to 31 December 2015).
More information about the performance measures that relate to these AZIP and AZPSP awards is set out in the Remuneration Committee Chairman's Speech and Presentation which was presented to shareholders at the Company's 2013 AGM, and which can be found at www.astrazeneca.com/Investors/Shareholder-information/Annual-General-Meeting.
A C N Kemp
Company Secretary
12 June 2013
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
|
Date: 12 June 2013
|
By: /s/ Adrian Kemp
|
| |
Name: Adrian Kemp
|
| |
Title: Company Secretary
|